A randomized, phase II, open-label, multicenter study investigating efficacy and safety of anti-PD-1/PD-L1 treatment +/- UV1 vaccination as first line treatment in patients with inoperable advanced or metastatic non-small cell lung cancer

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502437-25-00

Enrollment

141

Registered

2023-08-03

Start date

2022-08-15

Completion date

2024-09-12

Last updated

2024-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced or metastatic non-small cell lung cancer

Brief summary

Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) as determined by Blinded Independant Central Review (BICR)

Detailed description

Overall Survival (OS), Objective Response Rate (ORR), Disease Control Rate (DCR), Time To Recurrence (TtR), Duration of Response (DoR)

Interventions

DRUGLeukine

DRUGUV1

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) as determined by Blinded Independant Central Review (BICR)	—

Secondary

Measure	Time frame
Overall Survival (OS), Objective Response Rate (ORR), Disease Control Rate (DCR), Time To Recurrence (TtR), Duration of Response (DoR)	—

Countries

Norway

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026